共 131 条
[1]
Davies MJ(2018)Economic costs of diabetes in the US in 2017 Diabetes Care 41 917-928
[2]
D’Alessio DA(1998)Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 837-853
[3]
Fradkin J(1998)Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 352 854-865
[4]
Kernan WN(2019)6. Glycemic targets: standards of medical care in diabetes-2019 Diabetes Care 42 S61-S70
[5]
Mathieu C(2019)8. Obesity management for the treatment of type 2 diabetes: standards of medical care in diabetes-2019 Diabetes Care 42 S81-S89
[6]
Mingrone G(2019)9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019 Diabetes Care 42 S90-S102
[7]
Rossing P(2018)Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 41 2669-2701
[8]
Tsapas A(2018)Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist Sci Transl Med 10 eaar7047-1480
[9]
Wexler DJ(2019)Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial Diabetes Care 321 1466-50
[10]
Buse JB(2019)Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 Randomized Clinical Trial JAMA 3 SAT–139-961